Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis's oral MS drug fingolimod shows first Phase III efficacy

This article was originally published in Scrip

Executive Summary

Novartishas released positive data from the first Phase III trial of its novel oral multiple sclerosis therapy fingolimod (FTY720), showing that it led to a lower relapse rate than Biogen Idec's injectable drug Avonex (interferon beta-1a) a standard of care in the disease. However, the safety concerns which have troubled the drug in earlier trials, including skin cancer, remained a worry in the trial.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC007857

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel